Kentucky researchers push earlier detection for focal mucoid placentitis

Researchers at the University of Kentucky’s Gluck Equine Research Center say they’re pushing forward on earlier diagnosis and more targeted treatment for focal mucoid placentitis, or FMP, a sporadic but consequential equine placental disease linked to late-term abortion, stillbirth, and weak foals. In a May 17, 2026, Equine Disease Quarterly article republished by The Horse, Hossam El‑Sheikh Ali described work on blood-based proteomic biomarkers that could identify affected mares earlier than transabdominal ultrasound alone, alongside treatment studies examining which antibiotics can actually penetrate the disease’s characteristic thick mucoid lesions. The group is also using RNA sequencing to study inflammatory pathways, including Toll-like receptors, as potential therapeutic targets. (thehorse.com)

Why it matters: For equine veterinarians, the update underscores two practical realities: FMP is still poorly understood, and current treatment remains largely empirical. That matters because ultrasound can miss early or small lesions, while delayed detection narrows the window for intervention. Background data suggest the disease can materially affect foal viability and passive transfer: in one farm outbreak study, foals from affected mares were less likely to be viable at birth, weighed about 10 pounds less, and had roughly 30% lower blood IgG concentrations than controls, even though surviving foals later performed similarly to peers. (thehorse.com)

What to watch: Watch for validation of the proposed blood biomarker panel, plus field data on antibiotic penetration and whether those findings translate into a more standardized treatment protocol. (thehorse.com)